- Previous Close
2.5000 - Open
2.5000 - Bid 1.8300 x 100
- Ask 3.2100 x 100
- Day's Range
2.4600 - 2.7059 - 52 Week Range
2.0200 - 12.0000 - Volume
22,330 - Avg. Volume
2,251,023 - Market Cap (intraday)
6.55M - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
-- - EPS (TTM)
-4.2900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
www.lipella.comRecent News: LIPO
View MorePerformance Overview: LIPO
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIPO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIPO
View MoreValuation Measures
Market Cap
6.55M
Enterprise Value
5.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.09
Price/Book (mrq)
4.49
Enterprise Value/Revenue
10.89
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-108.95%
Return on Equity (ttm)
-231.67%
Revenue (ttm)
483.53k
Net Income Avi to Common (ttm)
-4.26M
Diluted EPS (ttm)
-4.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
1.35M
Total Debt/Equity (mrq)
4.85%
Levered Free Cash Flow (ttm)
-2.15M